2-TUR QANDLI DIABET BILAN OG‘RIGAN BEMORLARNI DAVOLASHDA EMPAGLIFLOZINNING GIPOGLIKEMIK VA KARDIOPROTEKTIV TA’SIRINI O‘RGANISH.

Maqola yon paneli

PDF (ruscha)
Nashr qilingan: 2023-02-05
DOI: https://doi.org/10.66073/researchfocus.v2i1.2819
Kalit so‘zlar:
2-toifa qandli diabet, aterosklerotik yurak-qon tomir kasalliklari, natriy glyukoza kortransporter 2 turi ingibitorlari, empagliflozin

Maqolaning asosiy mazmuni

Urunbaeva D.A.
Toshkent tibbiyot akademiyasi image/svg+xml
Najmutdinova D.K.
Toshkent tibbiyot akademiyasi image/svg+xml
Sadikova N.G.
Toshkent tibbiyot akademiyasi image/svg+xml
Gafurova D.S.
Toshkent tibbiyot akademiyasi image/svg+xml

Abstrak

Qandli diabet bilan og‘rigan bemorlarga ixtisoslashtirilgan yordam ko‘rsatish algoritmlariga (2019) ko‘ra, 2-tur diabet va YuQTK bilan og‘rigan bemorlarga gipoglikemik terapiyaning bir qismi sifatida yurak-qon tomir tizimiga isbotlangan natriy glyukoza kortransporter 2 turi ingibitorlari yoki glyukagonga o‘xshash peptid-1 retseptorlari agonistlaridan foydalanish tavsiya etiladi. Tadqiqotda Toshkent tibbiyot akademiyasi ko‘p tarmoqli klinikasining 2-terapiya bo‘limiga maslahat so‘rab murojaat qilgan 2-tur qandli diabetga chalingan 42 nafar bemor, jumladan, 21 nafar ayol va 21 nafar erkak ishtirok etdi. Kasallikning davomiyligi 3 yildan 8 yilgacha, o‘rtacha yoshi 56,6±9,8 yil. Ushbu bemorlar 2 guruhga bo‘lingan: 1-guruh - 18 bemorlar, metforminga kuniga 2000mg va 60 mg dozada sekin chiqariladigan gliklazid MB qo‘shilgan, 2-guruhga 24 bemor kiritilgan, ular metforminga 2000mg va empagliflozin 10 mg dozasida kuniga qo‘shilgan. Natijalar nazorat guruhiga nisbatan empagliflozinning metformin bilan yaxshi gipoglikemik ta’sirini ko‘rsatdi. Empagliflozin preparati yurak faoliyatiga ijobiy ta’sir ko‘rsatadi, bu yurakning urush fraksiyasini oshishi bilan tasdiqlanadi.

Maqola tafsilotlari

Nashr

Jild 2 Nomeri 1 (2023): Research Focus International Scientific Journal. 2-tom, 1-son (2023)

Bo'lim

Maqolalar
Creative Commons litsenziyasi

Ushbu asar Creative Commons Attribution 4.0 International litsenziyasi asosida litsenziyalangan.

Qanday iqtibos keltirish kerak

2-TUR QANDLI DIABET BILAN OG‘RIGAN BEMORLARNI DAVOLASHDA EMPAGLIFLOZINNING GIPOGLIKEMIK VA KARDIOPROTEKTIV TA’SIRINI O‘RGANISH. (2023). Research Focus International Scientific Journal, 2(1), 11-19. https://doi.org/10.66073/researchfocus.v2i1.2819

Adabiyotlar

Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й вып. (доп.). М.; 2021. [Standards of specialized diabetes care. Eds.: Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition (revised). М.; 2021 (in Russ.). DOI: 10.14341/DM12802.

American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B. et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125–S143. DOI: 10.2337/dc22-S009.

Бондаренко И.З., Бубнова М.Г. Что нового появилось в лечении пациента с сахарным диабетом и сердечно-сосудистыми заболеваниями: взгляд кардиологов. CardioСоматика. 2018; 9 (2): 24–30. DOI: 10.26442/2221- 7185_2018.2.24-30

Сергиенко И. В., Аншелес А. А., Халимов Ю. Ш., Шестакова М. В., Бойцов С. А. К21 КАРДИОЛОГИЧЕСКИЕ АСПЕКТЫ САХАРНОГО ДИАБЕТА 2 ТИПА. – Москва: Издательство «Перо», 2018 – 68 с.

Пьяных О.П. Многофакторное управление сахарным диабетом 2 типа у пациентов с очень высоким сердечно-сосудистым риском // Эндокринология: новости, мнения, обучение. 2021. Т. 10, № 3. C. 75–81. DOI: https://doi. org/10.33029/2304-9529-2021- 10-3-75-81

Cherney D.Z., Perkins B.A., Soleymanlou N. et al. Renal hemodynamic effect of sodium-glucose cotransporte r 2 inhibition in patients with type 1 diabetes mellitus // Circulation. 2014. Vol. 129. P. 587–597

Inzucchi S.E., Zinman B., Fitchett D. et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of theEMPA-REG OUTCOME trial // Diabetes Care. 2018. Vol. 41. P

IDF Diabetes Atlas. 9th edition. 2019. (Electronic resource.) URL: https://diabetesatlas.org/atlas/ninth-edition/ (access date: 21.01.2022).

Inzucchi S.E., Khunti K., Fitchett D.H., et al. 19-LB: consistent cardiovascular (CV) benefits from empagliflozin across the spectrum of CV risk factor control: post hoc analysis from EMPA-REG OUTCOME. Diabetes. 2019; 68 (1).

Zinman B., Wanner C., Lachin J.M., et al. Empaglifl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117–28.

HammoudiN, JeongD, SinghR, FarhatA, KomajdaM, MayouxE, HajjarR, LebecheD. Empagliflozin improves left ventricular diastolic dysfunction in agenetic model of type 2 diabetes. Cardiovascular Drugs and Therapy. 2017;31(3):233-246.]

Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovascular Diabetology. 2017;16(1):9

Rawshani A., Rawshani A., Franzén S., et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017; 376: 1407–18.

Эмпаглифлозин как новая стратегия ведения пациентов с сахарным диабетом 2 типа март 2017 г.Сахарный диабет 19(6):494